CD8A and neoplasm: In a preclinical study, the combination of JHU083 with an EGFR peptide vaccine (EVax) in homozygous EGFR‐mutant mice leads to enhanced tumor infiltration of CD8+ T cells and CD4+ Th1 cells with an increasing oxidative metabolism and improves tumor suppression compared with EVax monotherapy [310].